Marine Bio (MBII) Misses Q1 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% as AI buildout costs, Fed rate outlook weigh
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Piper Jaffray Cuts Price Target on Marine Bio (MBII) Following 1Q Report
May 13, 2016 7:58 AM EDTPiper Jaffray maintained an Overweight rating on Marrone Bio Innovations (NASDAQ: MBII), and cut the price target to $1.00 (from $2.00), following the company's 1Q earnings report. Marrone again beat Piper's top line expectations in the March ending quarter as sales growth in the specialty crop market continues to be stronger than expected, more than... More
